Quest Diagnostics Incorporated filings document a public diagnostic information services company with common stock listed on the New York Stock Exchange under DGX. The company’s 8-K reports disclose operating results, guidance updates, investor presentation materials, dividends, share repurchase authorizations, senior unsecured debt issuance and other material agreements tied to its capital structure.
Proxy filings describe annual meeting proposals, director elections, board committee assignments, governance practices, executive compensation and the company’s strategy for diagnostic testing insights, healthcare-provider relationships, data assets, automation and artificial intelligence. The filing record also documents shareholder voting matters and formal changes in board composition.
Quest Diagnostics Incorporated announced that Catherine T. Doherty will retire in July 2027. Effective November 1, 2026, she will transition to Executive Vice President, with responsibilities including health systems, the Company’s joint venture with Corewell Health, and Project Nova, a multi-year project to modernize its “Order to Cash” business processes, related information technology infrastructure and enabling technologies.
Her annual base salary remains $650,000, and her annual incentive compensation target remains 80% of base salary under the Senior Management Incentive Plan. The Committee approved an Employee Long-Term Incentive Plan award with a target value of $1,200,000, allocated entirely to restricted stock units, with a grant date of November 3, 2026.
Quest Diagnostics Inc. director Timothy C. Wentworth acquired 135 Phantom Stock Units on October 1, 2026, through elective deferrals of director cash compensation under the Quest Diagnostics Incorporated Amended and Restated Deferred Compensation Plan for Directors. His reported balance after the award was 477 Phantom Stock Units. The units become payable in cash upon termination of his service as a director.
QUEST DIAGNOSTICS INC (DGX) reported that CEO, President and director J. E. Davis sold 10,000 shares of common stock on September 1, 2026 at an average price of $242.72 per share in an open-market or private transaction. The transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the executive. Following this sale, Davis directly holds 122,423 shares of Quest Diagnostics common stock.
QUEST DIAGNOSTICS INC (DGX) insider James E. Davis has filed a notice under Rule 144 indicating an intention to sell up to 10,000 shares of common stock through Fidelity Brokerage Services LLC, with an indicated value of $2,427,200.00, and a proposed sale date of September 1, 2026 on the NYSE. The shares to be sold derive from restricted stock vesting awards granted as compensation in 2022 and 2024. The filing also notes that Davis sold 10,000 shares of common stock on June 1, 2026 for aggregate proceeds of $1,941,400.00.
QUEST DIAGNOSTICS INC (DGX) disclosed that Michael E. Prevoznik, SVP & General Counsel, exercised 22,677 stock options at $112.17 per share into common stock and, on the same date, sold 16,010, 6,237 and 430 common shares at weighted average prices of $242.8755, $243.6275 and $244.5148, respectively. The exercised option position was reduced to 0, and he also made a 1,000‑share charitable gift of common stock. Following these transactions, 5,780 shares are held indirectly through the company’s 401(k)/Supplemental Deferred Compensation Plan. The exercise and sales were effected under a Rule 10b5‑1 sales plan adopted by the reporting person.
QUEST DIAGNOSTICS INC (DGX) received a Rule 144 notice indicating that Michael E. Prevoznik plans to sell up to 22,677 shares of the company’s common stock through Fidelity Brokerage Services LLC. The shares relate to a stock option exercise, with a planned sale date of August 28, 2026 on the NYSE.
The filing lists an aggregate market value for the shares to be sold of $5,513,082.35. Quest Diagnostics common shares outstanding are reported as 110,373,360 as of the date referenced; this is a baseline figure, not the amount being sold.
T. Rowe Price Associates, Inc. filed an amended Schedule 13G reporting its beneficial ownership in Quest Diagnostics Inc. (common stock). The firm reports beneficial ownership of 5,428,244 shares, representing 4.9% of the class. It has sole voting power over 5,321,387 shares and sole dispositive power over 5,428,244 shares, with no shared voting or dispositive power. T. Rowe Price Associates states that this filing should not be construed as an admission that it is the beneficial owner of these securities, and such beneficial ownership is expressly denied.
Quest Diagnostics Inc. executive Mark E. Delaney, SVP & Chief Commercial Officer, reported selling 1,600 shares of common stock on 2026-07-28 at an average price of $235.18 per share. The sale was executed under a Rule 10b5-1 sales plan, and he now directly holds 10,335 shares.
DGX has a beneficial owner planning to sell common stock through Fidelity Brokerage Services LLC. The plan covers 1,600 common shares, with an indicated aggregate market value of 376,288.00, to be sold on or after July 28, 2026 on the NYSE. The disclosure also lists future restricted stock vesting events classified as compensation, including tranches of 400, 553, and 647 common shares scheduled to vest on February 12, 14, and 23, 2026, respectively.
Quest Diagnostics executive Karthik Kuppusamy, SVP Clinical Solutions, reported a small acquisition of 37 shares of common stock at $206.807 per share under a broker-administered dividend reinvestment plan, eligible for deferred Form 5 reporting under Rule 16a-6 but reported early. His direct holdings total 13,557 shares, with additional indirect holdings of 358 shares in a trust and 1,691 shares in the company’s 401(k) Profit Sharing Plan.